Novo Nordisk to Buy Forma Therapeutics for $1.1 Billion
- Posted by ISPE Boston
- On September 8, 2022
Watertown-based Forma Therapeutics, a clinical-stage biopharma focused on sickle cell disease (SCD) and rare blood disorders, is being acquired by Novo Nordisk for $1.1 billion. The acquisition includes Forma’s lead development candidate, etavopivat, and is aligned with Novo Nordisk’s strategy to complement and accelerate its scientific presence and pipeline in hemoglobinopathies, a group of disorders in which […]
Read More